How Biotech Startups Should Handle Milestone-Based Revenue 

Revenue recognition is one of the most technically demanding areas of accounting for any business. For biotech startups, it is particularly complex. Unlike a SaaS company that charges a monthly subscription fee or a manufacturer that ships a product and books a sale, biotech companies often structure their revenue around milestone payments, royalty arrangements, sublicensing fees, and collaborative research agreements that can span years and contain dozens of contingent obligations. 

Getting this right matters enormously. Incorrect revenue recognition is one of the most common audit findings for life sciences companies, and it has downstream consequences for your financial statements, your investor credibility, your audit readiness, and your ability to raise capital or enter partnerships in the future. This is not an area where you can afford to be approximate. 

This post will walk through the specific challenges biotech startups face with milestone-based revenue, the accounting framework that governs how it should be handled, and why having the right financial partner in place early is one of the most important investments a life sciences company can make. 

What Milestone-Based Revenue Actually Looks Like 

In a typical biotech collaboration agreement, a larger pharma company or institutional partner will commit to paying a series of payments contingent on the achievement of specific development, regulatory, or commercial milestones. Examples include a payment upon successful completion of Phase 1 clinical trials, a payment upon filing an IND or NDA, a payment triggered by FDA approval, and subsequent royalties based on commercial sales. 

These structures create significant accounting complexity because the timing and amount of revenue recognition must reflect the company’s actual performance obligations under the contract, not simply when cash changes hands. Under ASC 606, the revenue recognition standard that governs most biotech agreements, a company must identify each distinct performance obligation in the contract, allocate the total transaction price across those obligations, and recognize revenue only as each obligation is satisfied. 

This sounds straightforward in theory. In practice, it requires detailed contract analysis, significant judgment about what constitutes a distinct performance obligation, and ongoing monitoring of contract status to ensure that the recognition schedule reflects current facts. According to a 2022 analysis by Ernst and Young, revenue recognition under collaborative arrangements remains one of the top five audit adjustments for pre-commercial biotech companies in the United States. 

The Variable Consideration Problem 

One of the most challenging aspects of milestone-based revenue under ASC 606 is the treatment of variable consideration. Milestone payments are by definition contingent on future events, which makes them variable. The standard requires that variable consideration be included in the transaction price only to the extent that it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty is resolved. 

In plain language: you cannot recognize the value of a milestone payment before it is highly likely to be achieved. This creates a practical challenge because biotech development is inherently uncertain. Early-stage clinical milestones have meaningful failure rates. Regulatory outcomes are not guaranteed. The accounting has to reflect that uncertainty honestly, and that requires ongoing assessment of the probability of each milestone being achieved. 

This is not a one-time accounting decision. It is a continuous process that needs to be revisited every reporting period as clinical data becomes available, regulatory conversations progress, and the probability assessment changes. Companies that set up their revenue recognition framework correctly at the outset are in a much stronger position than those who try to retrofit their accounting after the fact when an audit or due diligence process requires it. 

Sublicensing and Royalty Arrangements 

Beyond milestone payments, many biotech collaborations include sublicensing fees and royalty streams that carry their own accounting complexities. An upfront sublicensing payment, for example, may need to be recognized ratably over the performance period of the license rather than entirely at the time of signing, depending on the nature of the license and the ongoing obligations of the licensor. 

Royalties present a different set of challenges. Under ASC 606, royalties based on sales or usage of a license are subject to a specific exception that requires them to be recognized only when the underlying sale occurs. This means you cannot accrue estimated future royalties in your revenue line. You recognize them as they are earned, based on actual partner sales data, which in many cases arrives on a quarterly lag. 

Building the operational infrastructure to track these different revenue streams, apply the correct recognition methodology to each, and produce financial statements that accurately reflect the economics of the arrangement requires accounting expertise that goes well beyond basic bookkeeping. It requires people who understand both the technical standards and the life sciences business model well enough to apply them correctly. 

The Audit and Investor Readiness Dimension 

For a biotech startup that aspires to raise institutional capital, conduct a PIPE or IPO, or enter major pharma partnerships, the quality of your revenue accounting is not just an accounting question. It is a credibility signal. Sophisticated investors and potential partners will look closely at how you have handled revenue recognition, and any inconsistencies or aggressive positions will raise concerns about the overall quality of your financial reporting. 

Escalon’s financial operations and fractional CFO services are built to help life sciences companies get this right from the beginning. We work with biotech clients to set up revenue recognition frameworks that are technically sound, well documented, and built to withstand audit and diligence scrutiny. This means reviewing your collaboration agreements in detail, documenting the performance obligations and allocation methodology, setting up the accounting system to apply the correct recognition logic, and preparing the disclosures that your financial statements will require. You can learn more about how Escalon supports life sciences companies at escalon.services/contact-us. 

Building the Financial Infrastructure Before You Need It 

One of the consistent themes we hear from biotech founders is that they underestimated how quickly their financial reporting complexity would increase once the first collaboration agreement was signed. What started as a company with zero or minimal revenue and straightforward accounting suddenly becomes an organization that needs to track multiple performance obligations across multiple agreements, prepare detailed revenue disclosures, and be ready to explain the accounting to investors, auditors, and potential partners. 

The cost of getting this wrong is high. Restatements are damaging. Audit adjustments erode credibility. Inconsistent revenue recognition across periods makes financial analysis difficult and raises red flags during capital raises. And fixing these issues retroactively is significantly more expensive and time-consuming than building the right framework from the start. 

Escalon works with biotech and life sciences companies at every stage of development to build the financial infrastructure that supports growth and withstands scrutiny. Our team combines technical accounting expertise with the operational horsepower to keep your books current, your reporting accurate, and your finance function ready for whatever comes next. 

Whether you have signed your first partnership agreement and need to set up revenue accounting correctly, or you are preparing for an audit and need to review your existing recognition policies, Escalon can help. Explore our financial operations and CFO advisory services at escalon.services/accounting and take the first step toward a finance function that is ready for what your science deserves.